136例小分子激酶抑制剂不良反应分析

doi:10.19803/j.1672-8629.20230148

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (10): 1163-1167.
DOI: 10.19803/j.1672-8629.20230148

136例小分子激酶抑制剂不良反应分析

贾贝¹, 王伟华¹, 杨靓², 戴媛媛^1,2,*

¹国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院药剂科,北京 100021;
²国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院肿瘤医院廊坊院区药剂科,河北廊坊 065001

收稿日期:2023-03-21 出版日期:2023-10-15 发布日期:2023-10-16
通讯作者: ^*戴媛媛,女,硕士,副主任药师,医院药学。E-mail：daiyuanyuan@aliyun.com
作者简介:贾贝,男,硕士,主管药师,临床药学。
基金资助:
中国医学科学院肿瘤医院管理研究课题（LC2021D04）

Analysis of 136 reports of adverse reactions related to small molecule kinase inhibitors

JIA Bei¹, WANG Weihua¹, YANG Liang², DAI Yuanyuan^{1, 2, *}

¹Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
²Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Langfang Campus, Chinese Academy of Medical Sciences, Langfang Hebei 065001, China

Received:2023-03-21 Online:2023-10-15 Published:2023-10-16

摘要/Abstract

摘要： 目的分析小分子激酶抑制剂（SMKI）药品不良反应（ADR）的发生特点,为临床合理用药提供参考。方法对本院2011年1月1日至2022年12月31日监测到的136例SMKI相关ADR进行分析,从患者基本情况、药品使用情况、ADR发生情况等方面探讨SMKI所致ADR的特点和风险。结果 136例患者共发生例次ADR,涉及21种SMKI,患者平均年龄（57.75±12.74）岁,肺癌患者占54.41%。34例ADR存在超说明书使用药品情况。ADR累及系统-器官以胃肠系统为主,其次为皮肤及皮下组织。54.41%的ADR患者未调整SMKI的用药剂量,16.91%为严重ADR病例,56.62%的ADR经过治疗好转。结论 SMKI相关ADR多数患者可耐受,部分患者需要减少给药剂量及对症处理,ADR可累及多个系统-器官。应指导患者开展针对性的ADR监测和管理,提高患者药物治疗的安全性和依从性。

关键词: 小分子激酶抑制剂, 药品不良反应, 口服靶向药物, 肺癌, 胃肠系统, 皮肤, 皮下组织, 表皮生长因子受体

Abstract: Objective To analyze the characteristics of adverse drug reactions (ADR) of small molecule kinase inhibitors (SMKI), and provide reference for rational use of drugs in clinic. Methods The data on 136 cases of SMKI-related ADR monitored in our hospital between 2011 and 2022 was analyzed while the characteristics and risks of ADR caused by SMKI were studied in terms of patients, drug use, and occurrence of ADR. Results One hundred and thirty-six cases of ADR involved 21 types of SMKI. The average age of the patients was 57.75±12.74, and patients with lung cancer accounted for 54.41%. There were 34 cases of off-label use of drugs. The systems-organs implicated in ADR were mainly the gastrointestinal system, followed by the skin and subcutaneous tissue. 54.41% of the patients with ADR did not have the dosage of SMKI adjusted, 16.91% were severe ADR cases, and 56.62% improved after treatment. Conclusion SMKI-related ADR are tolerable for most of the patients. Some patients require dose reduction and symptomatic treatment. ADR can implicate multiple systems-organs. Patients should be assisted in targeted ADR monitoring and management to improve the safety and compliance of medication.

Key words: small molecule kinase inhibitor, adverse drug reaction, oral targeted drug, lung cancer, gastrointestinal system, skin, subcutaneous tissue, EGFR

中图分类号:

贾贝, 王伟华, 杨靓, 戴媛媛. 136例小分子激酶抑制剂不良反应分析[J]. 中国药物警戒, 2023, 20(10): 1163-1167.

JIA Bei, WANG Weihua, YANG Liang, DAI Yuanyuan. Analysis of 136 reports of adverse reactions related to small molecule kinase inhibitors[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1163-1167.

参考文献

[1] BOURNEZ C, CARLES F, PEYRAT G, et al.Comparative assessment of protein kinase inhibitors in public databases and in PKIDB[J]. Molecules, 2020, 25(14): 3226.
[2] ROSKOSKI R JR.Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update[J]. Pharmacol Res, 2023, 187: 106552.
[3] SMITH P, LAVERY A, TURKINGTON RC. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management[J]. Best Pract Res Clin Gastroenterol, 2020, 48-49: 101691.
[4] COLEMAN EL, OLAMIJU B, LEVENTHAL JS.Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)[J]. Oncol Rep, 2021, 45(3): 891-898.
[5] AGARWAL M, THAREJA N, BENJAMIN M, et al.Tyrosine kinase inhibitor-induced hypertension[J]. Curr Oncol Rep, 2018, 20(8): 65.
[6] JIANG H, JIN Y, YAN H, et al.Hepatotoxicity of FDA-approved small molecule kinase inhibitors[J]. Expert Opin Drug Saf, 2021, 20(3): 335-348.
[7] MedDRA. MedDRA Version 25.1[EB/OL]. [2023-01-24]. https://www.meddra.org/how-to-use/support-documentation/english/welcome.
[8] National Medical Products Administration. Measures for the reporting and monitoring of adverse drug reaction(Decree No. 81 of the Ministry of Health) [EB/OL]. (2011-05-04) [2023-01-24]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504162501325_7.html.
[9] ZHENG R, ZHANG S, ZENG H, et al.Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[10] LONG CT, SHAO M, LU XY.Research progress on small molecule kinase inhibitors[J]. Acta Pharmaceutica Sinica(药学学报), 2021, 56(2): 414-431.
[11] ZHAO Y, CHENG B, CHEN Z, et al.Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 160: 103305.
[12] FU Y, WEI X, LIN L, et al.Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors[J]. Thorac Cancer, 2018, 9(5): 542-547.
[13] SKVRCE NM, GALIC I, PACADI C, et al.Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation[J]. Res Social Adm Pharm, 2020, 16(7): 928-934.
[14] The Drug Risk Management Group, Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Expert consensus of off-label drug use[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2015, 17(2): 101-103.
[15] MENG XY, LIANG YH, ATIHENIMU AMT, et al.Analysis of off-label use of 2000 outpatient anti-tumor drug prescriptions[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2022, 22(6): 758-760,764.
[16] WANG H, SU W, LOWE S, et al.Association of apatinib and breast cancer: a systematic review and meta-analysis[J]. Surgical Oncology, 2022, 44: 101818.
[17] The Expert Group on Off-label Use of Anlotinib. Expert consensus on off-label use of anlotinib[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2021, 38(24): 3102-3107.
[18] LIM M, SHULMAN DS, ROBERTS H, et al.Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center[J]. Cancer Med, 2020, 9(18): 6658-6666.
[19] FAN QQ, ZHANG B, ZHAO B, et al.215 cases of adverse drug reactions related to small molecule kinase inhibitors. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(5): 550-553,560.
[20] GOZZO L, VETRO C, BRANCATI S, et al.Off-label use of venetoclax in patients with acute myeloid leukemia: single center experience and data from pharmacovigilance database[J]. Front Pharmacol, 2021, 12: 748766.
[21] LIU S, KURZROCK R.Understanding toxicities of targeted agents: implications for anti-tumor activity and management[J]. Semin Oncol, 2015, 42(6): 863-875.
[22] AW DC, TAN EH, CHIN TM, et al.Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities[J]. Asia Pac J Clin Oncol, 2018, 14(1): 23-31.
[23] VERSMISSEN J, COLAFELLA KMM, KOOLEN SLW, et al.Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension[J]. Cardiovasc Res, 2019, 115(5): 904-914.
[24] ZAMORANO JL, LANCELLOTTI P, MUNOZ DR, et al.2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801.

136例小分子激酶抑制剂不良反应分析

Analysis of 136 reports of adverse reactions related to small molecule kinase inhibitors

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.